The characteristics of a hepatobiliary contrast agent are specific liver uptake and excretion via the biliary system. The paramagnetic substance (e.g. manganese, gadolinium) is taken up by normal hepatocytes. Diseased liver tissue did not include hepatocytes or their function is disturbed. Therefore, the signal of healthy liver tissue increases on T1 weighted sequences, but not in the liver lesions.
Another type of liver imaging contrast agent is superparamagnetic iron oxide. These particles accumulate in the reticuloendothelial system (RES) of the liver, and darken the healthy liver tissue in T2 weighted images. RES cells (including Kupffer cells) are existing in healthy liver tissue, in altered tissue with reduced RES activity or without RES cells the contrast agent concentration is also low or not existing, which improves the liver to lesion contrast.
Benefits of hepatobiliary contrast agents:
Differences of a hepatobiliary contrast agent compared with a targeted contrast agent for Kupffer cells:
See also Superparamagnetic Contrast Agents, Hepatobiliary Chelates, Liver Imaging, Endoremâ„¢, Primovistâ„¢, and Classifications, Characteristics, etc.

See also the related poll result: 'The development of contrast agents in MRI is'

Ferrioxamines are potential iron oxide-based intravascular contrast agents. Ferrioxamine methanesulfonate, ferrioxamine-B, and hydroxyethyl-starch-ferrioxamine have been tested as MRI contrast agents, partly in clinical trials.
Ferrioxamine methanesulfonate was tested as a paramagnetic agent for the imaging of the kidney and the urogenital system. Hydroxyethyl-starch-ferrioxamine has the potential to provide information regarding myocardial vascular flow and ferrioxamine-B derivatives may be used as hepatobiliary contrast agents.

See also Superparamagnetic Iron Oxide, Hepatobiliary Contrast Agents.

General MRI of the abdomen can consist of T1 or T2 weighted spin echo, fast spin echo (FSE, TSE) or gradient echo sequences with fat suppression and contrast enhanced MRI techniques. The examined organs include liver, pancreas, spleen, kidneys, adrenals as well as parts of the stomach and intestine (see also gastrointestinal imaging). Respiratory compensation and breath hold imaging is mandatory for a good image quality.
T1 weighted sequences are more sensitive for lesion detection than T2 weighted sequences at 0.5 T, while higher field strengths (greater than 1.0 T), T2 weighted and spoiled gradient echo sequences are used for focal lesion detection. Gradient echo in phase T1 breath hold can be performed as a dynamic series with the ability to visualize the blood distribution. Phases of contrast enhancement include the capillary or arterial dominant phase for demonstrating hypervascular lesions, in liver imaging the portal venous phase demonstrates the maximum difference between the liver and hypovascular lesions, while the equilibrium phase demonstrates interstitial disbursement for edematous and malignant tissues.
Out of phase gradient echo imaging for the abdomen is a lipid-type tissue sensitive sequence and is useful for the visualization of focal hepatic lesions, fatty liver (see also Dixon), hemochromatosis, adrenal lesions and renal masses. The standards for abdominal MRI vary according to clinical sites based on sequence availability and MRI equipment. Specific abdominal imaging coils and liver-specific contrast agents targeted to the healthy liver tissue improve the detection and localization of lesions.
See also Hepatobiliary Contrast Agents, Reticuloendothelial Contrast Agents, and Oral Contrast Agents.

For Ultrasound Imaging (USI) see Abdominal Ultrasound at Medical-Ultrasound-Imaging.com.

Contrast enhanced MRI is a commonly used procedure in magnetic resonance imaging. The need to more accurately characterize different types of lesions and to detect all malignant lesions is the main reason for the use of intravenous contrast agents.
Some methods are available to improve the contrast of different tissues. The focus of dynamic contrast enhanced MRI (DCE-MRI) is on contrast kinetics with demands for spatial resolution dependent on the application. DCE-MR imaging is used for diagnosis of cancer (see also liver imaging, abdominal imaging, breast MRI, dynamic scanning) as well as for diagnosis of cardiac infarction (see perfusion imaging, cardiac MRI). Quantitative DCE-MRI requires special data acquisition techniques and analysis software.
Contrast enhanced magnetic resonance angiography (CE-MRA) allows the visualization of vessels and the temporal resolution provides a separation of arteries and veins. These methods share the need for acquisition methods with high temporal and spatial resolution.
Double contrast administration (combined contrast enhanced (CCE) MRI) uses two contrast agents with complementary mechanisms e.g., superparamagnetic iron oxide to darken the background liver and gadolinium to brighten the vessels. A variety of different categories of contrast agents are currently available for clinical use.
Reasons for the use of contrast agents in MRI scans are:
Common Indications:
Brain MRI : Preoperative/pretreatment evaluation and postoperative evaluation of brain tumor therapy, CNS infections, noninfectious inflammatory disease and meningeal disease.
Spine MRI : Infection/inflammatory disease, primary tumors, drop metastases, initial evaluation of syrinx, postoperative evaluation of the lumbar spine: disk vs. scar.
Breast MRI : Detection of breast cancer in case of dense breasts, implants, malignant lymph nodes, or scarring after treatment for breast cancer, diagnosis of a suspicious breast lesion in order to avoid biopsy.

For Ultrasound Imaging (USI) see Contrast Enhanced Ultrasound at Medical-Ultrasound-Imaging.com. See also Blood Pool Agents, Myocardial Late Enhancement, Cardiovascular Imaging, Contrast Enhanced MR Venography, Contrast Resolution, Dynamic Scanning, Lung Imaging, Hepatobiliary Contrast Agents, Contrast Medium and MRI Guided Biopsy.

Cr-HIDA (Chromium diethyl HIDA meglumine) is a substance with paramagnetic characteristics that has been tested in animals for the use as a hepatobiliary MRI contrast agent.

See also Hepatobiliary Contrast Agents, Paramagnetic Substance, Paramagnetism.